Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Wei Meng

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Cell Death and Differentiation|March 28, 2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell deathJia Jia, Wenbo Ji, Antoine N Saliba, et al.
Nucleic Acids Research|October 16, 2025
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistanceCordelia D McGehee, X Wei Meng, Xinyan Wu, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Molecular Cancer|October 7, 2024
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitorsAnnapoorna Venkatachalam, Cristina Correia, Kevin L Peterson, et al.
Blood|December 3, 2014
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaCristina Correia, Paula A Schneider, Haiming Dai, et al.
NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Cell Death and Differentiation|March 28, 2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell deathJia Jia, Wenbo Ji, Antoine N Saliba, et al.
Nucleic Acids Research|October 16, 2025
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistanceCordelia D McGehee, X Wei Meng, Xinyan Wu, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Molecular Cancer|October 7, 2024
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitorsAnnapoorna Venkatachalam, Cristina Correia, Kevin L Peterson, et al.
Blood|December 3, 2014
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaCristina Correia, Paula A Schneider, Haiming Dai, et al.
NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Pageof 3